Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics

Richard T Arkwright, Rahul Deshmukh, Nikhil Adapa

  • 1Barbara Ann Karmanos Cancer Institute and Department of Oncology, School of Medicine, Wayne State University, 540.1 HWCRC, 4100 John R Road, Detroit, MI 48201- 2013. doup@karmanos.org.

Insights

Adenosine Monophosphate-Activated Protein Kinase (AMPK) regulates cellular processes and energy. Activating AMPK shows promise in cancer therapy by suppressing tumor growth, with natural compounds offering potential anticancer drugs.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Adenosine Monophosphate-Activated Protein Kinase (AMPK) is a crucial regulator of cellular energy homeostasis and various cellular functions.
  • AMPK plays a significant role in cancer development, with deficiencies promoting tumorigenesis and activation inhibiting tumor growth via mTORC1 signaling.

Purpose of the Study:

  • To review natural compounds and their derivatives that activate the AMPK signaling pathway.
  • To discuss the biology, history, anticancer roles, and mechanisms of action of AMPK-activating compounds.
  • To propose strategies for developing novel, selective AMPK activators for cancer therapy.

Main Methods:

  • Literature review of scientific publications on AMPK and its role in cancer.
  • Analysis of natural compounds and their derivatives with AMPK-activating properties.
  • Discussion of existing AMPK activators, such as Biguanides (Metformin, Phenformin).

Main Results:

  • AMPK activation suppresses tumor growth by inhibiting the mTORC1 pathway.
  • Natural compounds and their derivatives are emerging as potential anticancer agents by activating AMPK.
  • AMPK deficiencies are linked to enhanced cell proliferation and tumorigenesis.

Conclusions:

  • AMPK is a promising therapeutic target for cancer treatment.
  • Natural compounds offer a rich source for developing novel AMPK-activating anticancer drugs.
  • Further research is needed to develop selective and effective AMPK activators with reduced toxicity.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K